HYTN Innovations Inc (HYTN) AI Stock Analysis

• Market Cap: C$17.34M
• Dividend Yield: N/A
• Average Volume (3M): 12.09K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.47
• Revenue Growth: 47.86%
• EPS Growth: -225.43%
• Country: CA
• Employees: 7
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Beverages - Alcoholic
• EPS (TTM): >-0.01
• Shares Outstanding: 93,708,110
• 10 Day Avg. Volume: 8,619
• 30 Day Avg. Volume: 12,093
• PEG Ratio: -0.02
• Price to Book (P/B): -114.63
• Price to Sales (P/S): 23.29
• P/FCF Ratio: -24.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: C$0.00 ▼(-100.00% Downside)

HYTN Innovations Inc. faces significant financial challenges, with negative profitability and cash flow metrics being the most impactful factors. The technical analysis indicates bearish momentum, and the valuation is unattractive due to a negative P/E ratio and no dividend yield. These factors collectively result in a low overall stock score.

Positive Factors

Revenue Growth

HYTN Innovations Inc. has achieved significant revenue growth, indicating a strong demand for its products and services, which could lead to better financial performance in the future.

Diversified Revenue Model

A diversified revenue model helps HYTN mitigate risks associated with reliance on a single income stream, enhancing long-term financial stability.

Strategic Partnerships

Strategic partnerships expand market reach and create additional revenue opportunities, supporting sustainable growth and competitive positioning.

Negative Factors

Negative Profitability

Ongoing negative profitability indicates challenges in cost management and market competitiveness, potentially hindering long-term financial health.

Negative Cash Flow

Negative cash flow suggests reliance on external financing, which may not be sustainable, posing risks to liquidity and operational continuity.

Negative Equity Position

A negative equity position highlights financial instability and solvency risks, potentially limiting the company's ability to invest in growth opportunities.

HYTN Innovations Inc Business Overview & Revenue Model

Company Description

HYTN Innovations Inc. engages in the research, production, marketing, distribution, and sale of cannabis products for recreational consumers in Canada. It intends to offer infused sparkling beverages and infused edibles in various flavors. The company is headquartered in Vancouver, Canada.

How the Company Makes Money

HYTN generates revenue through a diversified model that includes direct sales of its proprietary software and hardware products, subscription-based services for ongoing software updates and support, and licensing agreements that allow third parties to use its technologies. Key revenue streams include the sale of communication devices, cloud-based software solutions, and consulting services for businesses looking to implement advanced communication systems. Additionally, strategic partnerships with major telecommunications providers and technology firms enhance HYTN's market reach and provide additional revenue opportunities through joint ventures and collaborative projects.

HYTN Innovations Inc Financial Statement Overview

Summary

HYTN Innovations Inc. is in a difficult financial position with negative profitability and cash flow metrics, coupled with a concerning balance sheet showing negative equity. While there is slight revenue growth, the company faces significant liquidity and solvency risks, necessitating strategic improvements to enhance financial health.

Income Statement

HYTN Innovations Inc. has shown some revenue growth, but profitability remains a concern with negative net income, EBIT, and EBITDA margins. The gross profit margin is slightly positive, indicating potential for future improvement, but the net profit margin remains deeply negative.

Balance Sheet

The company's balance sheet shows a negative equity position, indicating financial instability. The debt-to-equity ratio cannot be calculated due to negative equity, and the equity ratio is also negative, highlighting potential solvency issues.

Cash Flow

HYTN's cash flow statement reveals negative free cash flow and operating cash flow, suggesting cash burn. The company relies heavily on financing activities, which may not be sustainable long-term. There is no free cash flow growth, and the ratios to net income are challenging to assess with negative figures.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.28M	851.49K	763.46K	696.36K	0.00	0.00
Gross Profit	784.03K	287.44K	91.85K	121.65K	0.00	-840.00
EBITDA	-6.39M	-6.26M	-1.45M	-9.88M	-745.51K	-218.77K
Net Income	-6.76M	-6.61M	-2.33M	-17.38M	-959.48K	-313.78K
Balance Sheet
Total Assets	2.21M	2.38M	2.58M	3.79M	2.76M	797.02K
Cash, Cash Equivalents and Short-Term Investments	52.07K	256.58K	187.56K	1.03M	264.06K	176.47K
Total Debt	981.81K	793.56K	919.74K	887.22K	2.58M	161.32K
Total Liabilities	2.94M	2.56M	2.27M	1.71M	2.77M	51.17K
Stockholders Equity	-734.88K	-172.97K	314.72K	2.07M	-8.88K	745.86K
Cash Flow
Free Cash Flow	-915.73K	-804.21K	-1.18M	-2.38M	-1.67M	-624.70K
Operating Cash Flow	-896.81K	-783.36K	-1.18M	-2.16M	-693.52K	-276.70K
Investing Cash Flow	164.59K	162.67K	-4.10K	2.19M	-1.02M	-347.99K
Financing Cash Flow	492.87K	689.71K	346.17K	727.93K	1.80M	530.00K

HYTN Innovations Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.26
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:HYTN, the sentiment is Positive. The current price of 0.26 is above the 20-day moving average (MA) of 0.18, above the 50-day MA of 0.14, and above the 200-day MA of 0.18, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 58.89 is Neutral, neither overbought nor oversold. The STOCH value of 16.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:HYTN.

HYTN Innovations Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
CGII	46 Neutral	C$3.29M	-1.76	―	―	-25.05%	-19.86%
HYTN	38 Underperform	C$17.34M	-2.91	-9999.00%	―	47.86%	-225.43%

HYTN Innovations Inc Corporate Events

HYTN Hires German Firm MCS to Boost Investor-Focused Marketing

HYTN Innovations Inc. has engaged Germany-based MCS Market Communication Service GmbH to deliver a roughly 60-day marketing and communications program aimed at increasing investor and market awareness of the cannabis-focused pharmaceutical manufacturer. MCS, which is independent from HYTN and does not hold its securities, will be paid €50,000 in cash to review and refine HYTN’s existing materials, develop digital content and advertising, optimize keywords, and coordinate online campaigns targeting relevant investor audiences, signaling a focused push by HYTN to strengthen its visibility and positioning in regulated cannabis and psychoactive compounds markets.

HYTN Backs U.S. Move Toward Schedule III Cannabis, Citing GMP-Ready Platform

HYTN Innovations Inc. has welcomed a new U.S. executive order initiating the process to reclassify cannabis as a Schedule III controlled substance, a move that would recognize its medical use and bring it under federal pharmaceutical-style regulation via the FDA and DEA. Management says the company’s existing GMP-compliant infrastructure, Health Canada Drug Establishment and Cannabis Drug Licences, and international export operations leave it well positioned to participate in potential new regulatory and commercial opportunities that may emerge as the United States moves toward a more structured, pharmaceutical-grade framework for cannabis.